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Abstract
Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is a leading blood stage vaccine candidate. Plasmodium knowlesi
AMA1 (PkAMA1) was produced and purified using similar methodology as for clinical grade PfAMA1 yielding a pure,
conformational intact protein. Combined with the adjuvant CoVaccineHT
TM, PkAMA1 was found to be highlyimmunogenic in
rabbits and the efficacy of the PkAMA1 was subsequently tested in a rhesus macaque blood-stage challenge model. Six rhesus
monkeys were vaccinated with PkAMA1 and a control group of 6 were vaccinated with PfAMA1. A total of 50 mg AMA1 was
administered intramuscularly three times at 4 week intervals. One of six rhesus monkeys vaccinated with PkAMA1 was able to
control parasitaemia, upon blood stage challenge with P. knowlesi H-strain. Four out of the remaining five showed a delay in
parasite onset that correlated with functional antibody titres. In the PfAMA1 vaccinated control group, five out of six animals
had to be treated with antimalarials 8 days after challenge; one animal did not become patent during the challenge period.
Following a rest period, animals were boosted and challenged again. Four of the six rhesus monkeys vaccinated with PkAMA1
were able to control the parasitaemia, one had a delayed onset of parasitaemia and one animal was not protected, while all
control animals required treatment. To confirm that the control of parasitaemia was AMA1-related, animals were allowed to
recover, boosted and re-challenged with P. knowlesi Nuri strain. All control animals had to be treated with antimalarials by day
8, while five out of six PkAMA1 vaccinated animals were able to control parasitaemia. This study shows that: i) Yeast-expressed
PkAMA1 can protectagainst blood stage challenge; ii) Functional antibody levels as measured by GIA correlated inverselywith
the day of onset and iii) GIA IC50 values correlated with estimated in vivo growth rates.
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Introduction
The Plasmodium falciparum parasite is responsible for at least 300
million cases of malaria [1] and about 800,000 deaths every year
[2]. The majority of these deaths occur in children under five and
nulliparous women in sub-Saharan Africa [3]. An effective malaria
vaccine combined with existing anti-malarial strategies (e.g. indoor
residual spraying, bed-nets, antimalarial drugs etc.) would
certainly help to reduce malaria-related morbidity and mortality,
and as such would be a much needed addition to the arsenal.
The leading vaccine candidate Apical Membrane Antigen 1
(AMA1) was first discovered as a minor invariant merozoite
antigen in Plasmodium knowlesi [4,5] able to protect rhesus monkeys
from asexual blood stage challenge with P. knowlesi (Pk) [6]. The
protective effect of AMA1 vaccination has since been demonstrat-
ed in mouse and simian malaria models [7–9] and has spurred the
clinical development of P. falciparum AMA1 [7].
P. knowlesi causes a fulminent infection in rhesus monkeys, often
resulting in high parasitaemias similar to levels observed in P.
falciparum infections in humans, and ultimately in death if left
untreated [10–12]. P. knowlesi has recently also been shown to
infect humans under natural conditions and was shown to be a
contributing cause of death [13,14].
The clinical development of AMA1 has resulted in several trials
[15–19], including a phase IIa mosquito challenge of non-malaria
exposed volunteers [20] and a phase IIb trials in Malian children
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20547[21,22]. The phase IIa study did show a small, but significant,
delay in the pre-patent phase as determined by PCR data
modelling, whilst time to patency was similar in vaccinees and
controls, despite high Growth Inhibition Assay (GIA) titres in the
vaccinees [20]. One phase IIb study in Malian children using
Alum did not show any significant protection [22], whereas a
Phase IIb study using a potent adjuvant (AS02) revealed a modest
non-significant vaccine efficacy of about 17% when analysed
against all AMA1 alleles in infected subjects. The number of
parasites expressing the homologous 3D7-AMA1 was too low
allow for efficacy to be determined, but when data were analysed
for parasites expressing the homologous 3D7-AMA1 haplotype in
the highly polymorphic C1 region, vaccine efficacy was estimated
at 64% [23]. This has fuelled the debate whether vaccination with
AMA1 would have protective potential in humans.
The problem in pre-clinical and early clinical evaluation of a
vaccine is the lack of correlates of protection. This hampers vaccine
development, as without these correlates it is not clear what kind of
responses a vaccine needs to induce in order to protect. A recent
paper by Dutta et al. suggests that high titres of, functionally active,
antibodies against AMA1 are required for protection in a non-
human primate (Aotus) model [8]. We use non-human primate
models to establish correlates of protection, as an alternative to
rodent malaria models, that may be less representative for the
human malaria’s [24]. The Pk rhesus monkey model allows proof of
concept testing of P. falciparum and P. vivax vaccine candidates for
which Pk orthologs exist as well as evaluation of vaccines against
P. knowlesi. Humoral and cellular immune responses can be
evaluated in depth. Parasite challenge can be performed either by
infected mosquito bite, sporozoite injection (i.v., s.c. or i.d.) or i.v.
inoculation of infected red blood cells, and followed-up beyond
patency, allowing for a larger window of opportunity to detect
vaccine effects as compared to human phase IIa trials. Moreover,
rhesus monkeys can be infected repeatedly with P. knowlesi before
immunity develops [11]. Unlike clinical trials, trials in monkeys do
not require cGMP-grade materials (although at least GLP grade
antigen is preferred), and formal pharmacotoxicology testing is not
mandatory.Inaddition,preliminarysafetyprofileofvaccinescanbe
established in monkeys (behaviour, appetite, local reactions, clinical
chemistry and haematology).
In this study, we used P. knowlesi in Macaca mulatta (rhesus
monkey) as a model to test the efficacy of the blood stage vaccine
candidate AMA1. The vaccine antigen PkAMA1 was expressed in
the methylotrophic yeast Pichia pastoris, purified and quality
controlled similar to the cGMP production of PfAMA1 [25].
The antigen used in the control group, cGMP-grade PfAMA1
[25], induces PkAMA1 cross-reactive antibodies detectable in
ELISA, but results obtained in our laboratory have shown that
these antibodies do not have appreciable GIA activity when tested
on P. knowlesi.
A number of clinical studies, among others the one describing a
phase Ia clinical study, showed that the adjuvant AlhydrogelH is
not potent enough to achieve high antibody levels for AMA1
resulting in high GIA titres [15,16,22]. Therefore we used the
novel adjuvant, CoVaccine HT
TM that induces significantly
higher levels of functional antibodies to AMA1 than a proprietary
water in oil adjuvant, whilst being well tolerated by pigs and
macaques [26,27]. The active ingredients of CoVaccine HT
TM
are sucrose fatty acid sulphate esters (SFASE) and an oil-in-water
(squalane and Polysorbate-80) emulsion [26,28]. It has been shown
that this adjuvant enhances both humoral and cell mediated
responses when used with subunit vaccines [26]. CoVaccine
HT
TMis currently inclinicaldevelopment (http://www.clinicaltrials.
gov/ct2/results?term=CoVaccine+ht).
Here we report the parasitological and immunological results of
a rhesus macaque vaccination – blood-stage challenge study with
Pichia pastoris expressed PkAMA1 formulated with CoVaccine
HT
TM. We show that there is a correlation between functional
(GIA) antibody levels and the delay of onset of parasitaemia as well
as with in vivo parasite multiplication rates. The promising results
obtained here warrant clinical development of CoVaccine HT
TM
adjuvanted P. falciparum and, possibly, P. knowlesi AMA1 as
vaccines for life-threatening human Plasmodium infections.
Materials and Methods
Cloning of Plasmodium knowlesi ama1
A synthetic gene, codon optimised for expression in Pichia
pastoris, comprising domain I-II-III of Plasmodium knowlesi H strain
AMA1 (amino acids 43 to 487) (Genbank accession number
XM_002259303), was constructed by DNA2.0 (Menlo Park, CA).
Five Potential N-glycosylation sites were removed, by replacing
one of the amino acid in the NX[T/S] fingerprint with an amino
acid present in an AMA1 orthologue, analogous to what was done
for P. falciparum AMA1 [29]. Asn107 was replaced by Lys, Ser178
was replaced by Asn, Asn190 was replaced by Glu, Ser240 was
replaced by Arg and Asn441 was replaced by Gln. A PCR forward
primer (PkF: 59GGAATTCCCAATCATTGAGAGATC39) with
a5 9 EcoR1 restriction site and two reverse primers with 39XbaI
restriction sites (PkRIII: 59CGTCTAGACCTTCCTAGTAACA-
TTTTCTTC39; PkRII: 59GCTCTAGACCTGGAAACTCGT-
TGTCTAC 39) were used to amplify PkAMA1 domain I-II-III (aa
43–487) and PkAMA1 domain I-II (aa 43–387), respectively. PCR
products were cloned into EcoRI-XbaI sites of the pPicZaA vector
(Invitrogen, Leek, The Netherlands) in frame with the vector-
encoded myc-epitope and hexa-Histag. After transformation of
E. coli DH5a cells, plasmids were isolated, the sequence was
confirmed by DNA-sequencing (Baseclear, Leiden, The Nether-
lands), and used to transform P. pastoris KM71H following the
manufacturer’s protocols.
Selection of Pichia clones
Transfected P. pastoris were tested for protein production. Cells
were cultured in 10 mL glycerol-containing medium for 24–30 h
(30uC, 200 rpm). Cells were harvested by centrifugation and
resuspended in 4 mL methanol-containing medium, and then
cultured for 24 h. After low-speed centrifugation, the culture
supernatant was harvested and 20 mL of the culture supernatant
was analyzed by non-reducing SDS-PAGE with coomassie
brilliant blue staining or Western blotting with the reduction
sensitive monoclonal antibody R3/1C2 [4], which also served to
confirm the identity of the proteins.
Fermentation of Pichia pastoris
Fermentation runs for either construct were done in a 7 L
fermentor (Applikon, Schiedam, The Netherlands) with a starting
volume of 2 L. Fermentations were essentially performed
according to the instructions provided by the manufacturer of
the yeast strain and the vector (Invitrogen, Leek, The Netherlands)
for P. pastoris Mut
S cells [25].
Purification of recombinant PkAMA1 DI-II-III and PkAMA1
DI-II proteins
The methodology used for the production of PkAMA1 proteins
was similar to what was used for PfAMA1 [25]. Proteins were
purified using two chromatography purification steps, Nickel
IMAC affinity chromatography followed by size exclusion
chromatography. In brief, filtered culture supernatant was loaded
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Belgium). Washing was done with 10 column volumes of 20 mM
Na-phosphate, pH 7.8, 500 mM NaCl and 10 mM imidazole to
remove contaminating proteins. PkAMA1 proteins were eluted
with 20 mM Na-phosphate pH 7.8, 500 mM NaCl and 100 mM
imidazole. This fraction was exchanged into PBS using ultrafil-
tration concentrator tubes (10 kDa cutt-off; Millipore, Amsterdam,
The Netherlands). Protein fractions from different fermentations
were pooled and concentrated to 1 mL. Subsequently this fraction
was injected on a Superdex 75 preparative size exclusion
chromatography column (GE healthcare, Diegem, Belgium).
Fractions containing PkAMA1 proteins of 50 kDa (PkAMA1 D
I-II-III) or 40 kDa (PkAMA1 DI-II) were pooled, concentrated
and filter sterilised and then stored at 220uC.
SDS-PAGE
SDS-PAGE (NuPAGE Novex; Invitrogen, Leek, The Nether-
lands) 4–12% gradient gels were used with MES-buffer according
to the manufacturer’s instructions. For densitometry coomassie
blue stained gels were scanned with a GS-800 densitometer (Bio-
Rad) and analyzed with Quantity one software package version
4.5.
Conformational integrity assay for PkAMA1
Quantitative binding of PkAMA1 to the conformation-depen-
dent MAb [4] was determined as follows: MAb R3/1C2
(2 mg mL
21) was coupled to 1 mL cyanogen bromide (CNBr)
activated Sepharose 4 Fast Flow according to the manufacturer’s
instructions (Amersham Biosciences). Two-hundred mgo f
PkAMA1 DI-II-III, PkAMA1 DI-II and BSA were diluted in 3
volumes binding buffer (ImmunoPure A, Pierce, Rockford, IL).
Samples were separately passed over the immobilized R3/1C2
affinity column and the flow through was collected, and samples
containing AMA1 were confirmed to be negative for protein by
mBCA protein determination. After extensive washing with 10 bed
volumes PBS, bound proteins were eluted with 5–10 volumes 4.0
M NaSCN, pH 7.0. The eluted proteins were exchanged into PBS
and concentrated using ultrafiltration concentrator tubes (10 kDa
cut off; Millipore, Millipore, The Netherlands). The protein
contents in the eluate, flow-through and wash fractions were
estimated by mBCA.
Preparation of AMA1 vaccine formulations
PkAMA1 CoVaccine HT
TM (a novel proprietary vaccine
adjuvant of Protherics Medicines Development Limited, a BTG
Company, London, UK) formulations were prepared in a laminar
flow cabinet by mixing and gentle agitation of equal volumes of
antigen (200 mgm L
21 in PBS, pH 7.4) and CoVaccine HT
TM
adjuvant (40 mg mL
21 of Sucrose Fatty Acid Sulphate Esters
[SFASE] in a squalane o/w emulsion) in a glass vial. A 500 mL
vaccine dose contained 50 mg of antigen and 10 mg of SFASE.
Lyophilised cGMP PfAMA1 [4] was reconstituted with saline for
injection to a concentration of 200 mgm L
21 and then formulated
as above.
Ethics statement
For the rabbit immunisations, all animals were handled in strict
accordance with good animal practice as defined by the Belgian
national animal welfare regulations, and all animal work was
approved by the ethics committee of the Centre d’Economie
Rurale (CER Groupe, Marloie, Belgium). All rabbit handlings
were performed at Eurogentec SA, Seraing, Belgium, under
permit number LA 1800104.
All rhesus monkeys used in this study were captive bred for
research purposes. BPRC housing and animal care procedures are
in compliance with Dutch law on animal experiments, European
directive 86/609/EEC, and with the ‘‘Standard for Humane Care
and Use of Laboratory Animals by Foreign Institutions’’,
identification number A5539-01, provided by the Department of
Health and Human Services of the US National Institutes of
Health (NIH). The BPRC is compliant with the recommendations
of the Weatherall report ‘‘The use of non-human primates in
research’’(http://www.acmedsci.ac.uk/images/project/nhpdownl.
pdf).The independent ethics committee at BPRC, constituted
according to Dutch law on animal experiments, approved the
study protocol (number DEC 552) prior to start of the experiment.
In order to minimise suffering, venapunctures, immunisations and
passage of blood stage parasites, were performed on ketamine-
sedated monkeys. Animals were treated with antimalarials when the
parasitaemia following challenge exceeded 2%. Every day animals
were carefully observed for their general health (behaviour,
alertness, appetite and stool). In the event abnormalities were
observed, which did not happen during the course of this study, a
veterinarian was available at all times to take appropriate action.
During the course of the study all animals received a variety of
enrichment items (e.g. toys, food puzzles).
Rabbit immunisations
Rabbit immunisations were conducted at Eurogentec, Seraing,
Belgium under national animal welfare regulations. Two groups of
rabbits (N=5) were injected intramuscularly with 0.5 mL vaccine
containing 50 mg of purified PkAMA1 protein formulated in
CoVaccine HT
TM. Two booster injections of 50 mg were given at
days 28 and 56 after the primary dose. Bleeds were taken from
each animal before immunisation as well as two weeks after the
second immunisation. Exsanguination was done two weeks
following the last immunisation (day 70).
Vaccination, boost, and blood sampling of rhesus
macaque monkeys
12 healthy adult rhesus macaques weighing between 5 to 13 kg,
were selected for the study. The animals were all shown to be
negative for Plasmodium parasites, anti-PfAMA1 or anti-PkAMA1
antibodies. Animals were stratified over two groups of six animals,
with similar characteristics with respect to sex, age, and weight.
Treatments were then randomly assigned (Table 1). All vaccina-
tions and venapunctures were performed on ketamine-sedated
animals. Monkeys in the experimental group (N=6) were
immunised with 50 mg PkAMA1 DI-II-III (aa43–487) formulated
in CoVaccine HT
TM and the control monkeys (N=6) were
immunised with 50 mg GMP-grade PfAMA1 FVO strain DI-II-III
(aa25–545) formulated in CoVaccine HT
TM. Vaccines were given
intramuscularly in alternating upper legs on days 0, 28 and 56.
Table 1. Characteristics of rhesus monkeys at enrolment
(Range).
Treatment
Characteristic PkAMA1 PfAMA1
Gender (M : F) 4 : 2 3 : 3
Weight (kg) 8.3 (4.8 to 9.7) 8.4 (5.4 to 9.1)
Age (years) 7.3 (5.2 to 11.4) 7.2 (4.8 to 9.7)
doi:10.1371/journal.pone.0020547.t001
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and 14 following each vaccination. After the primary parasite
challenge animals were left to recover before a 50 mg booster dose
of Pk or PfAMA1 was given on day 203 and animals were re-
challenged two weeks later (day 217). The follow up was 35 days.
Monkeys were left to recover from the second challenge and were
boosted with 50 mg Pk or PfAMA1 on day 435, and challenged
again on day 450. Follow up time was 34 days (Figure 1).
Inspection of injection sites
Injection sites were inspected on days 0, 1, 7 and 14 following
each vaccination. Local reactions for oedema and erythema were
scored using the Draize scale [30]. A similar scoring system was
applied for the rating of induration and lymph node swelling.
Clinical chemistry and haematology
Standard parameters were determined for haematology (Sys-
mex XT 2000iV platform; Goffin Meyvis, Etten-Leur, the
Netherlands) and clinical chemistry (Cobas Integra 400; Roche
Diagnostics, Basel, Switzerland) on freshly obtained blood
samples. The following biochemical measurements were per-
formed on all blood samples taken on days 0, 1, 7 and 14 following
each vaccination: alkaline phosphatase, alanine transaminase,
aspartate transaminase, gamma glutamyl transpeptidase, bilirubin,
cholesterol, lactate dehydrogenase), urea, creatinine, albumin,
total protein, glucose, iron, calcium, sodium, potassium, chloride,
phosphate and HCO3
2. The following haematological measure-
ments were performed: erythrocyte count, haemoglobin, haema-
tocrit, mean corpuscular volume), mean corpuscular haemoglobin,
mean corpuscular haemoglobin concentration, white blood cell
count including leukocyte differentiation, platelet count and mean
platelet volume. The data were compared with reference values
obtained from healthy naive rhesus monkeys. Commercial kits
were used according to manufacturer’s instruction.
Blood stage parasites and challenge infection of rhesus
macaques
A parasite donor monkey negative for AMA1 antibody and
without previous exposure to malaria (also negative for Herpes-B,
Simian Retrovirus and STLV) was selected. Cryopreserved wild-
type P. knowlesi H strain was thawed according to the method
described by Trager et al. [31]. The parasite pellet (containing
mainly surviving rings) was allowed to recover in gassed complete
culture medium for 16 h at 37uC, in which time the parasites
developed to late trophozoites. 10,000 Freshly prepared late
trophozoites were injected i.v. into the donor monkey. Daily finger
pricks were taken from day 3 onwards. Parasitaemia was
monitored until it reached 1% (day 8), and 10 mL of blood was
drawn. The donor monkey was subsequently cured with
chloroquine (10 mg/kg i.m., ResochinH, Bayer, Leverkusen,
Germany) and pyrimethamine (1 mg/kg per os, Sigma, Zwijn-
drecht, The Netherlands) for three consecutive days. Cells were
extensively washed with RPMI 1640, and parasite infected cells
were adjusted to 1610
4 mL
21. All monkeys received 1 mL of this
parasite suspension containing 10,000 trophozoites i.v. in the vena
sapphena, followed by 5 mL of PBS to ensure the whole inoculum
was delivered. Finger prick blood samples were taken daily starting
from 3 days post infection and continued for three weeks for the
first challenge and five weeks for the second and third challenge.
Thin blood smears were prepared every day at approximately
15:00h when the majority of parasites were at ring stage.
Parasitaemias were determined by counting at least 4,000
erythrocytes in Giemsa-stained thin blood smears. Slides with
very low counts of infected red blood cells (iRBC) were arbitrarily
assigned a parasitaemia of 0.005%. Animals were cured if the
levels of parasitaemia reached $2% or at parasitaemias between 1
and 2% if high numbers of schizonts were observed. Treatment
was by i.m. injection of chloroquine and pyrimethamine as
described. At the end of each challenge phase (21 days for the
primary or 35 or 34 days for the second and third challenges,
respectively), all animals not yet cured were then treated with
chloroquine and pyrimethamine as described.
Antibody ELISA
96-well microtitre ELISA plates were coated with 50 ng protein
per well and incubated overnight at 4uC. Plates were washed and
blocked. Serum samples were diluted in serial two fold dilutions,
starting at 1/5,000 and were in duplicate added to antigen-coated
wells and incubated for 1 h at 37uC. A duplicate control dilution
series of a standard rabbit or rhesus anti PkAMA1 standard serum
pool was prepared from immune serum and included on every
plate. After extensive washing, the plates were incubated with
secondary antibodies goat anti-rabbit or anti-human immuno-
globulin G conjugated to alkaline phosphatase (Pierce, Rockford,
IL). Bound antibodies were visualized by adding the substrate
solution pNPP (para nitro phenyl phosphate, Sigma, Zwijndrecht,
The Netherlands) and incubated for 30 minutes at room
temperature. Absorbance at 405 nm was measured with a Bio-
Rad Microplate Reader 3550 (BioRad, Veenendaal, The Nether-
lands). A standard curve was constructed by four-parameter curve
fitting for every plate and titres of unknowns were calculated from
the four-parameter fit. Antibody titres were expressed as arbitrary
units (AU), where 1 AU corresponds to an amount of IgG
theoretically yielding an OD of 1 over background. Thus the titre
in AU indicates the dilution at which an OD of 1 over background
is achieved.
Figure 1. Study schedule. Timing of immunisations and challenges.
doi:10.1371/journal.pone.0020547.g001
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The in vitro anti-parasite activity of total IgG was determined by
P. knowlesi growth inhibition assays (GIA). Total IgG from serum
or plasma was purified on Protein A columns using binding and
elution buffers supplied by the manufacturer (Pierce, Rockford,
IL), exchanged into RPMI 1640 and concentrated to either
12 mg mL
21 for rabbit IgG or 20 mg mL
21 for monkey IgG
using ultra centrifugal devices (Millipore, Etten-Leur, The Nether-
lands), and subsequently filter sterilised through a 0.22-mm filter
(Millipore, Etten-Leur, The Netherlands). IgG antibodies were
aliquoted and frozen at 220uC until use. An alanine-synchronised
late stage (schizont) P. knowlesi (H-strain) culture was adjusted to
1% parasitaemia and 4% haematocrit in 40% normal human
serum and 30 mgm L
21 gentamycin. Purified IgG was added in a
volume of 30 ml in a 96-well flat-bottomed tissue culture plate
(Greiner, Alphen a/d Rijn, The Netherlands), to which 30 mLo f
the parasite culture was added. Samples were tested in triplicate at
four IgG concentrations; viz. 6, 3, 1.5 and 0.75 mg mL
21 for
rabbit or 10, 5, 2.5 and 1.25 mg mL
21 for rhesus IgG. The
highest IgG concentration (10 mg mL
21) used for rhesus GIA
corresponds to the total IgG concentration in undiluted rhesus
serum, thus GIA activity at 10 mg mL
21 can be interpreted as an
estimate of GIA activity in undiluted rhesus serum. The inhibitory
mAb R3/1C2 (1.5 mg mL
21) and EDTA (4 mM) were also
included in every test plate as positive controls. The final
concentration of the culture was 1% parasitaemia at 2%
haematocrit and 20% normal human serum. Plates were
incubated at 37uC under a 5% O2,5 %C O 2, 90% N2 moist
atmosphere for one cycle (26–30 h). Every assay was routinely
performed in triplicate. Parasite specific lactate dehydrogenase
(pLDH) activity, a measure for the total number of parasites, was
measured using standard protocols [32].
Inhibition was calculated as 1006[12((OD650 of infected RBCs
with tested IgG2OD650 of uninfected RBCs)/(OD650 of infected
RBCs with pre-immune IgG2OD650 uninfected RBCs))]. GIA
assays were performed in two separate batches; all assays up to and
including the second challenge were done in one batch. GIA
assays for the third challenge were done independently from the
aforementioned series.
Lymphocyte stimulation assays
PBMCs were isolated from heparinised peripheral blood by
density gradient centrifugation using lymphocyte separation
medium (Invitrogen, Leek, The Netherlands) at 2100 rpm for
15 minutes without brake at room temperature. Cells at the
interphase were collected and washed twice with RPMI 1640
medium. The PBMCs were resuspended in 8% foetal calf serum
(FCS) (ICN, The Netherlands) in RPMI 1640 medium and
adjusted to 2610
6 cells mL
21. The cell suspension (100 mL) was
added in triplicate to 96 well round bottom plates (2610
5 cells
well
21). One-hundred mL culture medium containing AMA1
antigen was added to a final AMA1 concentration of 10 mgm L
21.
Concanavalin A was added as positive control at a final
concentration of 5 mgm L
21. Cells were incubated at 37uCi n
5% CO2 atmosphere for 3 days. Supernatant was harvested and
stored at 220uC until further use.
Cytokine measurement by ELISA
Culture supernatants were thawed at room temperature and
assayed for IFN-c and IL-13 using macaque IFN-c and IL-13
ELISA kits (U-Cytech Biosciences, Utrecht, The Netherlands)
according to the manufacturer’s instructions. Recombinant IFN-c
or IL-13 were used as standards. Concentrations of unknowns
were estimated using a four-parameter fit on the standard curve.
Data are presented as background corrected values, i.e. back-
ground (medium only) is subtracted from the stimulated values.
Relation between GIA and in vivo parasite growth
In vivo growth was estimated for all animals. The initial
parasitaemia was calculated by dividing the inoculum (10,000)
by the total numbers of red blood cells (estimated by weight and
average RBC) and multiplied by four (assuming four infectious
merozoites arise from one trophozoite). The parasitaemia
observed at patency was then divided by the initial parasitaemia,
yielding the multiplication factor between infection and day of
patency plus one. The average per day in vivo growth rate was then
calculated by taking the day of patency
th root of the multiplication
factor. In the event animals became patent, without increasing
parasitaemia in the days following patency, the last occurrence of
patency observed was used for calculations. This yields a
conservative estimate, as it could be argued that these animals
did not require treatment and thus were protected and could be
analysed similar to animals that did not become patent at all.
Animals that did not become patent were arbitrarily assigned the
last day of observation. Average per day in vivo growth rates in
controls for the three separate challenges were calculated,
excluding the non-responder animal for the first two challenges,
and were used for subsequent in vivo growth inhibition (IVGI)
calculations. IVGI was calculated as follows: 1006(12(growth in
PkAMA1 animal/average growth in PfAMA1 group)).
Statistical analysis
All statistical analyses were performed with the R language and
environment for statistical computing (R Foundation for Statistical
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://
www.R-project.org). Evaluation of statistical significance for IgG
levels was performed on log-transformed titres and IgG titres are
presented as geometric means with 95% confidence intervals (95%
CI). Differences in GIA titres were analysed by t-test and GIA
titres are presented as arithmetic means with 95% CI (the percent
sign used in conjunction with GIA titre differences throughout the
paper should be interpreted as percent points). IFN-c and IL-13
levels are presented as medians with P25 and P75 percentiles,
between group comparisons were done using the non-parametric
Mann-Whitney test and paired data (between time points) were
analysed using Wilcoxon signed rank test. GIA and log-
transformed IgG between time-point comparisons were done
using paired t-tests. Survival data (time to patency or time to drug
cure) were evaluated using log-rank tests.
The relation between IgG and the GIA titres was investigated
by non linear least squares regression using the following formula:
GIA=100 * 1/[1 + Exp((Ln IC502Ln IgG) * Slope)], where IgG
is the antibody titre (PkAMA1 specific IgG in AU mL
21 or total
IgG in mg mL
21) and IC50 represents the IgG concentration
yielding 50% inhibition. Slope is a parameter indicating the
steepness of the curve, with steeper curves at higher values. As
Slope is rather difficult to interpret it is expressed as the fold-
increase in IgG required to raise GIA levels from 10 to 90%. (It
can be shown algebraically that this is: e
[ln(9) – ln(1/9)]/Slope, which is
approximately e
(4.394/Slope) and for an increase from 10 to 50% or
50 to 90% this is approximately e
(2.197/Slope)). IC50 and Slope
values were estimated from GIA data for each animal at 4 different
total IgG concentrations (viz. 1.25, 2.5, 5 and 10 mg mL
21) using
a non-linear mixed effects model employing the GIA parameter-
isation described above. This method reduces 4 GIA data points at
different total IgG concentrations to two parameters (viz. IC50 and
slope) and thus makes full use of the GIA titration data. The IC50
value represents the amount of total IgG required to obtain 50%
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activity in a serum, with lower IC50 values representing more
potent GIA activity. The results of the fitting procedure are
depicted in Figure S1, and IC50 values are indicated.
Results
Production, purification and quality control of PkAMA1
The Pichia pastoris expression system was used to produce
AMA1 from P. knowlesi H strain (amino acids 43–487 and aa 43–
387), with potential N-glycosylation sites removed. Several runs
in a 7-Liter fermentor were performed and subsequently the
protein was purified using Ni-IMAC, as the protein contains a
hexa-histidine tag. Gel filtration was used in the second step,
essentially for buffer exchange and for the removal of excess of
dimers. Yields were approximately 2 and 40 mg mL
21 for
PkAMA1 D I-II-III and PkAMA1 D I-II, respectively.
table-2-captionThe apparent molecular masses of the two
constructs analyzed by 4–12% gradient SDS-PAGE were
50 kDa and 40 kDa for PkAMA1 DI-II-III and PkAMA1 DI-
II respectively, in accordance with theoretical mass calculated
from their respective amino acid sequences. Figure 2 shows that
both products are near to apparent homogeneity. Reduction of
PkAMA1 D I-II-III protein samples resulted in the appearance
of two additional low molecular weight bands (Figure 2). The
apparent size of the two smaller products is in accordance with
the location of a proteolytic cleavage site in DII, observed in
PfAMA1 FVO and 3D7 [25,32]. Densitometric analysis of SDS-
PAGE on the non-reduced samples revealed that 96% of the
protein was in the main band for PkAMA1 DI-II-III and 99%
for PkAMA1 DI-II. Densitometry on the reduced samples
showed that less than 10% and 3% of the protein is internally
cleaved, for PkAMA1 DI-II-III and PkAMA1 DI-II, respectively.
Both proteins react with anti hexa-histidine antibodies, anti myc-
antibodies and with the PkAMA1 specific antibody R3/1C2
(data not shown), as expected.
As it has been shown that immunisation with reduced and
alkylated AMA1 results in low functional antibody titres [33], we
designed an assay to assess the conformational intactness of the
protein, by a quantitative binding assay to immobilized R3/1C2,
essentially as described before [25]. R3/1C2 recognizes a
reduction-sensitive epitope [4]. Eighty-eight (88%) percent of
PkAMA1 (DI-II-III) was bound to immobilized R3/1C2.
Comparative immunogenicity studies and growth
inhibition in rabbits using the novel adjuvant CoVaccine
HT
TM
The protein products made were first tested for immunogenicity
in rabbits. These experiments were, given the low yield of the full
length PkAMA1, also used to select the antigen of choice for the
rhesus study, as unpublished studies by ourselves and those of
Lalitha and co-workers [34] suggest that PfAMA1 domain I and II
is nearly as good as PfAMA1 domain I, II and III at inducing
growth inhibiting antibodies. To this end, two groups of five
rabbits were immunised with 50 mg of either PkAMA1 DI-II-III or
PkAMA1 DI-II adjuvanted with CoVaccine HT
TM. Immunisa-
tions were given at days 0, 28 and 56, and a final bleed was taken
at day 70. Unfortunately one rabbit in the PkAMA1 DI-II group
died during the immunisation phase from causes not related to the
vaccination. Titres to full length PkAMA1 (Domains I, II & III)
were similar in both groups with 370.6 (95% CI 205.4 to 670.0)
and 315.4 (95% CI 169.0 to 588.8) kAU mL
21 for PkAMA1 (DI-
II-III) versus (DI-II) respectively (t-test, p=0.595). The same
observation was made for PkAMA1 domains I & II. Geometric
mean titres were 205.9 (95% CI 108.8 to 389.7) and 256.9 (95%
CI 140.2 to 470.8) kAU mL
21 for PkAMA1 DI-II-III versus Pk
DI-II, respectively (t-test, p=0.483). At an IgG concentration of
6m gm L
21, GIA titres were, however, significantly higher in the
PkAMA1 (DI-II-III) group at 64.5% (52.8 to 76.3) versus 43.5%
(24.0 to 62.9) in the PkAMA1 (D I & II) group (t-test, p=0.032).
This trend was consistent for 3, 1.5 and 0.75 mg mL
21 IgG (t-test,
Figure 2. SDS-PAGE gel of vaccine antigens. SDS-PAGE gel of Pichia pastoris produced PkAMA1 DI-II-III, A non-reduced and B reduced, PkAMA1
DI-II, C non-reduced and D reduced. Lane 1, 10 mg; lane 2, 5 mg; lane 3, 2.5 mg; lane 4, 1.25 mg.
doi:10.1371/journal.pone.0020547.g002
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was decided to use PkAMA1 DI-II-III for the rhesus vaccinations.
Safety and local reactions in rhesus macaques
All 12 rhesus monkeys in the study were carefully observed in
their behaviour (general, vividness, appetite) and monitored for
their general health (weight, stool) during the full course of the
study. At day 1, 7 and 14 following the vaccinations at days 0, 28
and 56, blood samples were taken and analysed for haematological
and clinical chemistry parameters. Both vaccine formulations were
well tolerated. No vaccine related serious adverse events (i.e. an
event which hypothetically might have caused death if it were
more severe) were observed. For all but two animals, body weights
remained unchanged during the observation period. One animal
in the PkAMA1 group had a decreased appetite between days 8
and 15. No oedema, erythema or hypersensitivity reactions were
observed at the injection sites. Following vaccination three animals
in PkAMA1 group and one animal in PfAMA1 had a slight
swelling in the draining inguinal lymph node that resolved within
two weeks. Three animals in the PfAMA1 group developed a
transient muscle induration at the site of injection following
vaccination. After each immunisation, one animal in the PfAMA1
group experienced muscle induration at the point of injection with
a maximum size of 2.5 cm. These indurations resolved within two
to four weeks and did not influence the animals’ behaviour.
In general, none of the animals showed persistent deviations
from the reference values during the course of the study. Acute
effects of sedation and sampling were evident, and are generally
observed during vaccination studies. Elevations following vacci-
nation were observed in white blood cell count, basophil count and
monocytes. These returned to baseline values within 14 days after
each vaccination. Neutrophil levels increased to above normal
values with a concomitant drop in free serum iron. Both resolved
within 14 days after immunisation.
Blood-stage parasite challenge
At day 70, all animals were blood stage challenged by in vivo
passage of 10,000 P. knowlesi H strain late trophozoites. The left
hand panels in figure 3 show the parasitaemia in the blood of
individual animals during the course of infection, both in the
immunised (top panel) and control (bottom panel) group. Table 2
shows the parasitological and immunological data at the day of
challenge. Five animals from the control group had to be cured
within 8 days, the sixth animal, however (R01041 [N]) did not
become patent during the challenge phase (Figure 3, Table 2).
One monkey from the PkAMA1 group, (Ri9980203 [e]) was
patent at days 10 and 14 post infection, but was obviously able to
control the parasitaemia (Table 2). The other 5 animals had to be
cured, but there was an average delay of about 2 days in the day of
onset of the parasitaemia between the PkAMA1 group and the
PfAMA1 control group, albeit not statistically significant (log-rank
test, p=0.453). The time to drug cure was also delayed for 4 out of
6 animals, but again not statistically significant (log-rank test,
p=0.28). When these analyses were repeated excluding the
control monkey that did not become patent (R01041 [N]), both
time to patency and time to drug cure were significantly longer in
the PkAMA1 vaccinated group (log-rank test, p=0.006 and 0.002,
respectively).
Immunological analysis of the first phase of the study
Figure 4 shows that all animals had low anti-PkAMA1-IgG
levels before vaccination (14 95% CI 6 to 34 and 32 95% CI 17 to
61 AU mL
21, for PkAMA1 and PfAMA1 groups respectively).
Following vaccination, animals in the PkAMA1 group had
detectable levels of antibodies to PkAMA1 two weeks after the
first immunisation (939, 95% CI 358 to 2460 AU mL
21, paired
t-test with day 0, p=0.0006). Anti PkAMA1-IgG also increased in
the PfAMA1 group, but at a much lower rate (118, 95% CI 51 to
271, paired t-test with day 0, p=0.0005). The second immuni-
sation at day 28 boosted responses at day 56 to high levels in the
PkAMA1 group (22.3, 95% CI 11.7 to 42.6 kAU mL
21, paired
t-test with day 28, p=0.0002). PkAMA1-IgG levels in the
PfAMA1 group were also boosted significantly after the second
immunisation (3.2, 95% CI 1.6 to 6.5 kAU mL
21, paired t-test
with day 28, p=0.0006). At day 56 anti-PkAMA1-IgG levels were
significantly higher in the PkAMA1 group (7.0 fold, 95% CI 3.0 to
16.0 fold, t-test p- value=0.0004). The third vaccination at day 56
boosted anti PkAMA1-IgG levels at day 70 even further; animals
in the PkAMA1 group had 70.5 kAU mL
21 (95% CI 43.2 to
115.1, paired t-test with day 56, p=0.0002) and animals in the
PfAMA1 had 45.5 kAU mL
21 (95% CI 21.5 to 96.5, paired t-test
with day 56, p,0.0001). This was in part due to one animal
(Ri397 [e]) in the PfAMA1 group that had an unexpectedly high
anti PkAMA1 titre (164.0 kAU mL
21) at day 70 and this value
was confirmed in repeat ELISA’s. In parallel, the IgG titre to the
PfAMA1 vaccine antigen was also high in this animal
(266.6 kAU mL
21). Day 70 IgG levels to PkAMA1 were not
significantly higher in the PkAMA1 group [70.5 (95% CI 43.2 to
115.1) versus 45.5 (95% CI 21.5 to 96.5) kAU mL
21 (p=0.24)] as
compared to the PfAMA1 group. IgG levels to PkAMA1
decreased during the challenge phase in both groups (PkAMA1
group: paired t-test with day 70, p=0.0122 to 45.9 kAU mL
21
95% CI 27.5 to 76.5 and PfAMA1 group: paired t-test with day
70, p=0.0052 to 18.1 kAU mL
21 95% CI 10.5 to 31.3).
Figure 5 shows the GIA titres in the two treatment groups. The
first two immunisations at days 0 and 28 induced clearly detectable
GIA activity in the PkAMA1 vaccinated animals and GIA levels
had reached 41.3% at day 42 (95% CI 15.6 to 67.0, paired t-test
with day 0, p=0.0218) between days 0 and 42 (figure 5). By
contrast GIA levels in the PfAMA1 group did not change
significantly (22.7%, 95% CI 22.9 to 6.6% at day 42, paired
t-test with day 0, p=0.226) (figure 5). The third immunisation
increased GIA levels even further in the PkAMA1 group to 78.4%
at day 70 (95% CI 61.8 to 94.9%, paired t-test with day 42,
p=0.003), while GIA levels remained unchanged in the PfAMA1
group 1.9% (, 95% CI 212.6 to 7.2%, paired t-test with day 42,
p=0.437). At the time of challenge (day 70) GIA levels were
significantly higher in the PkAMA1 group as compared to the
PfAMA1 control group (t-test, p,0.0001) (figure 5). GIA levels in
the PkAMA1 group decreased significantly during the challenge
phase to 46.7% (95% CI 15.2 to 78.3%, paired t-test with day 70,
p=0.0128) and a small non-significant decrease was observed for
animals in the PfAMA1 group; 218.2% at day 91 (295% CI
235.1 to 21.4%, paired t-test with day 70, p=0.053).
Antigen-specific lymphocyte stimulation assays showed that
IFN-c levels were generally low with a median values of 25.4
(Quartile range: 17.7 to 36.3 pg mL
21) and 1 (Quartile range 1 to
1p gm L
21) for the PkAMA1 and PfAMA1 groups, respectively.
The difference in IFN-c levels was statistically significant
(p=0.025, Mann-Whitney test). The protected monkey in the
PkAMA1 group produced the highest IFN-c level upon stimula-
tion with PkAMA1, while all other samples were low to negative in
this assay (Figure 6). IL-13 levels were low; the median IL-13
values were 14.5 (Quartile range 2.8 to 84.2 pg mL
21) and 33.8
(Quartile range 8.2 to 91.5) for the PkAMA1 and PfAMA1 groups,
respectively (p=0.68, Mann-Whitney test). The IL-13 level of the
protected monkey was not elevated; in the PkAMA1 group only
two monkeys (R00066 [#] and Ri9902011 [&]) had elevated
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animal in the control group that did not become patent did not
produce detectable IFN-c nor IL-13 upon stimulation with
PkAMA1. Four out of two control monkeys (Ri10177 [&],
Ri9806051 [X], Ri397 [e] and R01077 [%]) in the control
group produced some IL-13, but no detectable IFN-c.
Plasmodium knowlesi blood-stage challenge after
booster vaccination
The results described above obtained after the primary
challenge prompted us to extend the study with an additional
boost and second challenge, similar to Deans and co-workers [6].
Vaccine and control animals received one additional booster
immunisation of 50 mg PkAMA1 or PfAMA1, respectively, 203
days following the first vaccination. At day 217 the animals were
re-challenged with 10,000 P. knowlesi H strain parasites. The
parasitaemias for the second challenge are depicted in the top
middle and bottom middle panels of figure 3 and parasitological
and immunological data are provided in table 2.
Five out of 6 control monkeys were chloroquine-treated before
or at day 8 post-challenge. The sixth animal (R01041 [N]), the
same monkey that did not become parasitaemic after the first
challenge, became patent on days 7 and 12; it had a delay of the
onset of parasitaemia, but required treatment at day 16 post-
challenge (Figure 3).
Four rhesus monkeys in the PkAMA1 group were able to control
the parasitaemia (Figure 3). In these four animals the parasitaemia
onset varied between day 7 (R97025 [%]) and day 34 (R00066
[#]). One rhesus monkey (Ri9902033 [X]) in the PkAMA1 group
became patent 5 days post challenge and was treated 8 days post-
challenge, the sixth monkey (R02013 [N]) became patent at day 9
and was treated on day 17 (Figure 3, Table 2). Time to patency and
time to drug cure were significantly delayed in the PkAMA1 group
(p=0.009 and 0.0029, respectively).
Figure 3. Parasitaemia development following i.v. challenge with P. knowlesi blood stage parasites. Parasitaemia development versus
time during the 3 challenges. Top panels are PkAMA1-immunised experimental animals and bottom panels PfAMA1-immunised control animals. Day
8 post challenge is indicated by a vertical red line. The symbols within each treatment group refer to the same animals throughout all figures.
doi:10.1371/journal.pone.0020547.g003
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Monkey Symbol Protected DoP DoT
in vivo
Growth IVGI Pf IgG Pk IgG GIA10 IC50 IC10–90
PkAMA1-immunised (verum) animals
First Challenge
R00066 # No 6 10 4.34 35.2 7.83 50.00 62.75 6.27 10.67
R02013 $ No 7 9 3.84 42.7 32.89 93.89 75.75 4.90 8.29
R97025 % No 7 11 5.06 24.4 14.27 38.53 76.41 5.47 9.21
Ri9902011 & No 9 12 2.85 57.4 51.52 142.53 79.42 4.76 8.07
Ri9980203 e Yes 10/14 21 1.84 72.5 35.01 77.57 108.05 3.33 6.12
Ri9902033 X No 6 8 6.21 7.3 21.56 61.56 67.90 7.66 13.74
Second Challenge
R00066 # Yes 34 35 1.36 74.1 39.42 162.81 98.71 1.66 11.19
R02013 $ No 9/13 17 2.07 60.6 51.32 176.47 93.51 2.64 10.36
R97025 % Yes 7/12 35 2.02 61.6 47.09 168.62 89.36 2.66 10.35
Ri9902011 & Yes 10 35 2.32 55.7 49.35 126.28 96.46 3.01 10.12
Ri9980203 e Yes 18 35 1.63 69.0 50.04 129.95 104.64 1.67 11.20
Ri9902033 X No 5 8 5.61 27.0 34.43 50.79 37.11 12.10 8.26
Third Challenge
R00066 # Yes 15/19/24 34 1.51 72.6 45.7 135.7 85.5 0.94 119.8
R02013 $ Yes 16/25/29 34 1.44 73.8 44.8 168.3 89.5 3.40 15.4
R97025 % Yes 18/21/22 34 1.48 73.1 60.1 230.9 82.1 2.71 19.2
Ri9902011 & Yes 14 34 1.93 65.0 129.5 365.9 83.7 1.72 34.2
Ri9980203 e Yes 6/18 34 1.65 70.2 52.9 203.9 83.0 0.54 1166.2
Ri9902033 X No 7 9 5.35 3.0 33.8 56.9 45.3 11.32 7.0
PfAMA1-immunised (control) animals
First Challenge
R00080 # No 5 7 6.89 22.9 132.9 22.2 7.4 nc nc
R01041 $ No 21 21 1.46 78.2 116.4 38.8 3.9 nc nc
R01077 % No 5 7 7.77 216.1 163.1 50.7 22.4 nc nc
Ri10177 & No 5 8 7.35 29.8 293.7 27.0 5.4 nc nc
Ri397 e No 5 8 6.13 8.4 266.6 170.2 1.2 nc nc
Ri9806051 X No 5 8 5.33 20.4 164.0 44.2 24.2 nc nc
Second Challenge
R00080 # No 5 7 4.99 4.9 206.6 18.3 10.2 nc nc
R01041 $ No 7/12 16 1.94 63.0 141.1 17.5 216.9 nc nc
R01077 % No 5 7 5.50 24.9 160.7 31.0 217.1 nc nc
Ri10177 & No 5 7 5.69 28.4 141.0 32.0 213.7 nc nc
Ri397 e No 5 8 4.79 8.7 159.0 27.4 24.5 nc nc
Ri9806051 X No 5 8 5.26 20.3 144.9 40.8 21.4 nc nc
Third Challenge
R00080 # No 7 8 5.34 3.1 394.5 71.4 28.4 nc nc
R01041 $ No 6 8 4.41 20.0 161.8 9.8 6.6 nc nc
R01077 % No 5 8 7.95 244.3 323.3 23.9 24.9 nc nc
Ri10177 & No 6 8 6.37 215.4 188.0 32.3 11.6 nc nc
Ri397 e No 6 8 4.51 18.1 212.5 11.9 211.3 nc nc
Ri9806051 X No 6 8 4.49 18.5 174.2 26.8 9.2 nc nc
DoP=day of patency multiple patency events are separated by a slash, DoT=day of treatment, in vivo Growth=estimated in vivo multiplication per cycle, IVGI=in vivo
growth inhibition calculated as outlined in materials and methods, Pf IgG and Pk IgG=the Pf and Pk IgG titre, respectively, at the time of parasite challenge, GIA10=the
observed GIA titre at 10 mg mL
21 total IgG at the time of parasite challenge, IC50=the amount of total IgG (mg mL
21) required for 50% inhibition at the time of
parasite challenge, IC10–90=the fold difference between the total IgG concentrations required for 10 and 90% GIA titres at the time of parasite challenge.
Slope=Parameter that indicates the steepness of the sigmoid GIA versus IgG curve. nc=Not Calculated.
doi:10.1371/journal.pone.0020547.t002
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On the day of re-boost, anti-PkAMA1-IgG antibodies had
decreased significantly in both groups compared to the levels after
challenge (day 91) (PkAMA1 group: 11.2 kAU mL
21, 95% CI 7.0
to 18.0, paired t-test with day 91, p=0.0013 and PfAMA1
group:2.4 kAU mL
21, 95% CI 1.8 to 3.1, paired t-test with day
91, p=0.0052) (Figure 4). Boosting was effective and at the time of
the second challenge (day 217) IgG levels had risen to
126.2 kAU mL
21 (95% CI 77.3 to 206.0, paired t-test with day
202, p,0.0001) and GIA levels had increased to 86.6% in the
PkAMA1 group (95% CI 60.6 to 112.7%, paired t-test with day
202, p=0.0002) (Figures 4 and 5). Anti-PkAMA1-IgG levels in the
PfAMA1 group showed an increase to 26.6 kAU mL
21 (95% CI
18.8 to 37.8, paired t-test with day 202, p,0.0001). GIA levels
increased only slightly in the PfAMA1 group to 23.4% (95% CI
220.2 to 13.4%, paired t-test with day 202, p=0.0530). At the
time of challenge IgG and GIA levels were significantly higher in
the PkAMA1 group (IgG: 4.7-fold, 95% CI 2.8 to 8.1-fold, t-test,
p,0.0001 and GIA: 90.1% higher, 95% CI 62.6 to 117.5%,
p,0.0001).
IgG antibody levels and GIA titres in the PkAMA1 group were
slightly higher compared to the values obtained on day 70 (IgG
levels: 1.79-fold 95% CI 0.884 to 3.62-fold, paired t-test,
p=0.0875 and GIA 8.2% higher, 95% CI 215.8 to 32.3, paired
t-test, p=0.42). On day 252 at the end of the second challenge,
anti PkAMA1-IgG levels were unchanged in the PkAMA1 group
(1.03-fold, 95% CI 0.45 to 2.4, paired t-test, p=0.92) and
significantly decreased in the PfAMA1 group (0.52-fold, 95% CI
0.40 to 0.69, paired t-test, p=0.00172).
For the PkAMA1 immunised group, GIAs done on IgG
obtained five weeks after the second challenge did not decrease
as markedly as after the first challenge (10% decrease, 95% CI
25.8 to 26.0%, paired t-test, p=0.163) (figure 5). Conversely,
GIA levels increased during the challenge in the PfAMA1 group
(17.8% increase, 95% CI 25.6 to 41.2%, paired t-test,
p=0.1086). The four protected animals in the PkAMA1 group
had low GIA IC50 values at the time of challenge. The animal
(R02013 [N]) with a low IC50 of at 2.6 mg mL
21 at the time of
challenge was drug cured on day 17, and the animal (Ri9902033
[X]) with the highest IC50 was drug cured 8 days after challenge
(Table 2).
IFN-c levels did not change significantly between days 70 and
202 in the PkAMA1 group with a median value of 159.9 (Quartile
range: 84.5 to 189.0 pg mL
21) (Wilcoxon signed rank test,
p=0.16). In the PfAMA1 group, however, IFN-c levels increased
significantly between days 70 and 202 to 81.4 (Quartile range:
34.4 to 107.2 pg mL
21. Day 202 IFN-c levels were not statistically
different between the two groups (Mann-Whitney U test, p=0.13)
(Figure 6). IFN-c levels decreased in both groups following booster
vaccination (day 217) (Wilcoxon signed rank test on pooled data
for PkAMA1 and PfAMA1, p=0. 0015), with median values of
40.1 (Quartile range: 14.3 to 147.1 pg mL
21) and 8.4 (Quartile
range: 6.3 to 18.0 pg mL
21), for PkAMA1 and PfAMA1 groups,
respectively. IL-13 levels did not change appreciably between days
Figure 4. IgG antibody levels to the PkAMA1 vaccine antigen. Blue triangles on the x-axis indicate immunisations and red triangles indicate
time of parasite challenge. PkAMA1=PkAMA1-immunised experimental animals, PfAMA1=PfAMA1-immunised control animals.
doi:10.1371/journal.pone.0020547.g004
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(Figure 6). Booster vaccination resulted in an increase in IL-13
levels in both groups (Wilcoxon signed rank test on pooled data for
PkAMA1 and PfAMA1, p=0.012). The two monkeys in the
PkAMA1 group that required drug treatment had low IFN-c levels
at the day of challenge, whereas three out of the four protected
monkeys had clearly detectable IFN-c levels at the time of
challenge. The monkey in the control group (R01041 [N]) with a
delay in parasitaemia did not have detectable levels of IFN-c nor
IL-13 (Figure 6).
Protection after re-boost and heterologous blood-stage
challenge with Pk Nuri strain
To investigate whether the protection observed upon the second
challenge was AMA1-mediated, monkeys were boosted with Pk or
PfAMA1 and challenged with the Pk Nuri strain. The Pk Nuri
AMA1 differs by only one amino acid from the H-strain, whilst
other antigens expressed on the surface of infected erythrocytes
that may contribute to protective responses (e.g. Schizont-Infected
Cell Agglutination, SICA-Var) are expected to be different in a
heterologous strain [11]. The heterologous challenge thus applies
to parasite antigens other than AMA1, a situation considerably
different from P. falciparum where the chance of finding two very
closely related AMA1 molecules in different isolates is very small.
The parasitaemias for the third challenge are depicted in the top
right and bottom right panels of figure 3 and parasitological and
immunological data are shown in table 2. All animals in the
control group required treatment by day 8, while five out of six
PkAMA1 vaccinated rhesus monkeys were able to control the
parasitaemia, albeit not sterilely (Figure 3, Table 2). Low numbers
of unhealthy appearing parasites were occasionally observed in
these five animals (R00066 [#] days 15, 19 and 24, R02013 [N]
days 16, 25 and 29, R97025 [%] days 18, 21 and 22, R9902011
[&] day14 and R9980203 [e] days 6 and 18) (Table 2). Time to
patency and time to drug cure were significantly longer in the
PkAMA1 group (log-rank test, p=0.009 and 0.0009 for patency
and cure, respectively). One monkey in the PkAMA1 group
(R02033 [X]) could not control parasitaemia and required drug
cure by day 9. This was the same monkey that did not show any
signs of protection in the two previous challenges.
Immunological analysis of the third challenge
On the day of re-boost, anti-PkAMA1-IgG antibodies had
decreased significantly to 15.0 kAU mL
21 (95% CI 6.8 to 33.4,
paired t-test with day 252, p=0.0008) for the PkAMA1 group and
to 3.1 kAU mL
21(95% CI 2.0 to 4.6, paired t-test with day 252,
p,0.0001), for the PfAMA1 groups compared to the levels after
the second challenge (Figure 4). Boosting was effective and at the
time of the third challenge (day 450), PkAMA1-IgG antibody
levels had increased to 167.9 kAU mL
21 in the PkAMA1 group
and to 23.6 kAU mL
21 in the PfAMA1 group (95% CI 87.0 to
324.0, paired t-test with day 435, p,0.0001 and 11.1 to 50.1,
paired t-test with day 435, p=0.0004 for Pk and PfAMA1 groups,
respectively). At the time of the third challenge, anti PkAMA1-IgG
levels were 7.1-fold higher (95% CI 3.0 to 17.0, t-test, p=0.0005)
in the PkAMA1 group as compared to the PfAMA1 group. Anti
Figure 5. Parasite Growth Inhibition by purified IgG antibodies. GIA titres with P. knowlesi H-strain at 10 and 5 mg mL
21 IgG for PkAMA1
immunised experimental group and PfAMA1 immunised controls. Blue triangles on the x-axis indicate immunisation time points, red triangles
indicate time of parasite challenges.
doi:10.1371/journal.pone.0020547.g005
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period in both groups; to 89.9 (95% CI 52.6 to 153.8, paired t-test
with day 450, p,0.0001) in the PkAMA1 group and to 13.2 (95%
CI 7.5 to 23.3, paired t-test with day 450, p=0.007) for the
PfAMA1 group.
GIA levels appeared lower at day 450 as compared to day 217,
but as these were determined in two independent runs, direct
comparisons between days 217 and 450 can, unfortunately, not be
made. GIA levels in the PkAMA1 group increased significantly
following booster vaccination to 78.2% (95% CI 61.0 to 95.3,
paired t-test with day 435, p=0.0007). By contrast, GIA levels in
the PfAMA1 group remained unchanged at 0.5% (95% CI 29.8
to 10.8%, paired t-test with day 435, p=0.88). During the
challenge phase, there was a tendency for decreasing GIA levels in
the PkAMA1 group to 70.3% (95% CI 47.2 to 95.3%, paired t-test
with day 450, p=0.073), whereas GIA levels in the PfAMA1
group increased significantly to 18.3% (95% CI 4.9 to 31.7%,
paired t-test with day 450, p=0.024).
IFN-c levels increased significantly in both groups between the
end of the second challenge (day 252) and the day of the second
booster vaccination (day 435) (Wilcoxon signed rank test on pooled
data for PkAMA1 and PfAMA1, p=0.0005). Vaccination resulted
in a significant decrease of IFN-c production in both groups
(Wilcoxon signed rank test on pooled data for PkAMA1 and
PfAMA1, p=0.001) (Figure 6). Levels of IFN-c did not change
significantly during the challenge phase (Wilcoxon signed rank test
on pooled data for PkAMA1 and PfAMA1, p=0.30). IL-13 levels
did not change significantly between the end of the second challenge
and the day of the second booster vaccination in both groups
(Wilcoxon signed rank test on pooled data for PkAMA1 and
PfAMA1, p=0.92) (Figure 6). Booster vaccination, however,
induced a significant increase in IL-13 levels in both groups
(Wilcoxon signed rank test, p=0.0024) (Figure 6). IL-13 levels
appeared to decrease in both groups during the challenge phase, but
this failed to achieve statistical significance (Wilcoxon signed rank
test on pooled data for PkAMA1 and PfAMA1, p=0.11) (Figure 6).
Figure 6. IFN-c and IL-13 production following in vitro stimulation with PkAMA1. Blue triangles on the x-axis indicate immunisation time
points, red triangles indicate time of parasite challenges. PfAMA1=PfAMA1-immunised control animals, PkAMA1=PkAMA1-immunised experimental
animals. The point not depicted for PkAMA1 [e] is at 2757 pg mL
21 IFN-c.
doi:10.1371/journal.pone.0020547.g006
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The relation between IgG and GIA was investigated by
modeling a sigmoid curve using non-linear least squares
regression. Day 0 samples from both groups were included and
PkAMA1 vaccinated animals were used for time points thereafter.
Analysis was restricted to GIA values from one GIA run at
10 mg mL
21 IgG, which corresponds to the amount of total IgG
present in rhesus serum (days 42, 70, 91, 202, 217 and 252). Thus
the amounts of GIA and PkAMA1-specific IgG both correspond to
values obtained with undiluted serum or plasma. The relationship
between GIA and PkAMA1-specific IgG is graphically presented
in figure 7. The correlation coefficient was 0.908 (95% CI 0.841 to
0.948, p,0.0001). The IC50 value was estimated at 38 kAU mL
21
P. knowlesi AMA1-specific IgG (95% CI 31 to 46) and the fold
difference in IgG between 10 and 90% GIA was estimated at 15.4
fold (95% CI 7.8 to 59.5) (Figure 7).
Correlates of Protection: Relation between GIA and in
vivo growth inhibition
During the first challenge estimated In vivo growth rate (Table 2
and Figure 8) was correlated with GIA IC50 values (Spearman’s
Rho=0.94, p=0.017). This correlation did not change when
recalculated with the assumption that monkey Ri9980203 was
patent on day 10 or considered protected. This correlation was
also independent of the assumption that the inoculation of one late
trophozoite yielded four infected red blood cells (iRBC). Changing
number of iRBC arising from one inoculated late trophozoite,
however, did change the estimated growth rates in the vaccinated
and in the control animals that developed parasitaemia (8.8, 6.7
and 5.8 for 1, 4 or 8 iRBC arising from one inoculated
trophozoite, respectively) and in the vaccinated animals as well.
The protected animal had an IC50 value of 3.3 mg mL
21 IgG
(IVGI, 72.5%), and the three monkeys with a delayed onset of
parasitaemia in the first challenge had IC50 values of 4.8 (day 9,
IVGI, 57.4%), 4.9 (day 7, IVGI 42.7%) and 5.5 (day 7, IVGI
24.4%) mg mL
21 IgG, respectively. The two non-protected
PkAMA1 animals, patent at day 6, had IC50 values of 6.3 (IVGI,
35.2%) and 7.7 (IVGI, 7.3%) mg mL
21 IgG, respectively (Table 2).
The animal in the control group for which no parasites were
detected did not have high levels of anti-PkAMA1 antibodies, nor
detectable GIA activity.
The significant correlation between GIA IC50 values and in vivo
growth was confirmed during the second challenge (Spearman’s
Rho=0.94, p=0.017) (Figure 8). When the correlation was
recalculated using the first occurrence of patency for the
estimation of in vivo growth rate, the correlation coefficient was
0.83 and not significant (p=0.058). At the second challenge the
four protected monkeys had IC50 values ranging between 1.7 and
3.0 mg mL
21 IgG; the monkey with a delay had an IC50 of
2.6 mg mL
21, whereas the non-protected animal had an IC50
value of 12.1 mg mL
21 IgG (Table 2).
At the third challenge the five protected animals all had IC50
values lower than 3.4 mg mL
21 IgG and the non-protected
animal had an IC50 value of 11.1 mg mL
21 IgG (Table 2). The
correlation between GIA IC50 and in vivo growth rate was,
however, not observed at the third challenge (Spearman’s
Rho=0.03, p=1.0).
Discussion
The rhesus Plasmodium knowlesi model enables the investigation
of in vivo protection following (repeated) mosquito or blood-stage
challenge with a longer observation window as compared to
challenge studies in humans. The model also offers the
opportunity to assess clinical safety in non-human primates. This
safety evaluation includes clinical observations (behaviour, appetite
injection site inspection etc.) as well as full haematology and
clinical chemistry evaluations. Therefore the rhesus Plasmodium
knowlesi model can be a valuable tool for the down-selection of
human malaria vaccine candidates and formulations (provided a
Pk orthologue is available).
The main findings of the work reported here are: i.) Vaccination
with heterologously-expressed PkAMA1 formulated with a potent
adjuvant protects rhesus monkeys from subsequent blood-stage
challenge (i.e. animals are able to control parasitaemia). ii.)
Protection appeared to be mainly antibody-mediated, although a
contribution of cellular immunity cannot be excluded. iii.) High
levels of growth inhibiting antibodies are required for protection.
iv.) The degree of protection improves upon repeated infection
and boosting. v.) Protection against blood-stage infection can be
induced by the use of a single antigen.
The results presented here are in agreement with the findings by
Deans et al. [6], here confirmed with heterologously-expressed
antigen and an adjuvant that can be used in human trials. Similar
to results obtained by Deans et al. [6], solid protection was only
achieved following challenge and booster vaccination. A series of
Figure 7. The relation between GIA and IgG titre. The IC50 value is
indicated by red lines. The various colours represent the time points at
which samples were taken: day 42 dark blue, day 70 orange, day 91
light blue, day 202 green, day 217 purple and day 252 red.
doi:10.1371/journal.pone.0020547.g007
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yield high enough antibody and/or T-cell responses to confer
protection. It is possible that exposure to live parasites followed by
booster immunisation contributed to a more balanced humoral
and cellular response.
The data suggest that high levels of growth inhibiting antibodies
are required for protection. Moreover, in vitro and in vivo growth
inhibition are correlated. Based on the correlation between
parasitological measures (IVG, day to patency or day to treatment)
and GIA IC50 values it is tempting to speculate that in this
experiment growth inhibiting antibodies are the main mediators of
protection. This is in agreement with the results from Dutta et al.
in the Aotus P. falciparum model [8], the observation that passive
transfer of hyperimmune IgG can abrogate parasitaemia [35] and
that transplacental IgG provides protection in neonates [36,37].
The PkAMA1 vaccinated animal that was protected during the
first challenge had high GIA and IFN-c levels. At the second and
third challenge, however, IFN-c increased in all animals (including
non-protected controls) to levels similar as observed in the
aforementioned animal. Thus high IFN-c levels alone are not a
correlate, although it cannot be excluded that Ag-specific IFN-c
production enhances antibody-mediated protection. Of note is
that IFN-c levels increased after challenge and decreased following
booster vaccinations, whereas the inverse was observed for IL-13
levels. Overall a gradual increase in IFN-c levels was observed for
the Pk and PfAMA1 groups over the 3 challenges, suggesting
improved cellular immune responses. In mice it has been
demonstrated that AMA1-specific T-cells play an important role
in the protection against P. chabaudi [38], suggesting that the
improved cellular responses may have contributed to the
protection observed at the second and third challenge.
Results obtained with heterologous prime-boost regimens with 4
antigens (2 pre-erythrocytic and 2 blood-stage, including AMA1)
combined show that rhesus monkeys can be protected from
sporozoite challenge [39,40]. Some animals became patent, but
were able to control parasitaemia, similar to what is reported here.
Unexpectedly, the protected animals in the study by Weiss et al.
did not have appreciable GIA levels at the time of challenge and
GIA levels only developed during challenge [41], suggesting that T
cells induced by vaccination provided help for antibody formation
upon parasite exposure. GIA and anti AMA1 or MSP119 IgG
levels at the time of drug cure, however, were similar in animals
that were able to control the parasitaemia and animals that were
not [41]. This suggest that other, non identified, cell-mediated
mechanisms may account for the protection, as IFN-c levels at the
time of challenge did not explain the ability to self cure [39]. The
increase of GIA titres during challenge is in contrast with data
presented here; GIA levels waned during the first and second
challenges in all 6 and 4 out of 6 PkAMA1 vaccinated animals.
During the third challenge 3 PkAMA1 vaccinated animals
retained their titre (,5% drop) and 3 decreased. The number of
animals able to retain GIA levels increased with each challenge
thus it appears that boosting and parasite exposure improves
immune responses in PkAMA1 vaccinated animals, possibly
through the expansion of AMA1-specific T cell responses.
The results presented here indicate that high GIA levels are
required for protection (IC50#3.5 mg mL
21), but these levels
wane quickly, even when exposed to parasites. This begs the
question on how long protective levels can be maintained. The
vaccination regimen used here closely resembles the WHO
Expanded Programme on Immunisation comprising immunisa-
tions at 6, 10 and 14 weeks, and a vaccination at 9 months of age
(www.who.int). Several papers indicate that immunisation timing
[42], prime boost regimes or a combination of schedule and prime
boost may be more effective at eliciting both cellular and antibody
responses [39,43]. It is tempting to speculate that combinations of
prime with DNA or viral vectors (e.g. adenovirus, attenuated pox
viruses, attenuated measles, virosomes or other virus-like particles)
followed by a (heterologous) virally vectored and protein adjuvant
boost would induce high humoral and cellular responses and
thereby yield more solid protection. Whether such an immune
response elicited by prime boost schedules is higher, persist longer
and would protect upon the first challenge remains to be
investigated.
The protection observed in the work reported here appears in
contrast with results from a recent phase IIa study [20] where only
a small, biologically non relevant, delay in pre-patent modelled-
PCR data was observed despite high GIA titres to the,
homologous, challenge strain. The phase IIa study involved
mosquito challenge of volunteers, whereas the infection of the
Figure 8. Relation between measured in vitro and estimated in vivo parasite growth. Relation between GIA IC50 values and estimated in
vivo growth during the three intravenous parasite challenges.
doi:10.1371/journal.pone.0020547.g008
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10,000) iRBC. It is possible that sporozoite passage through the
skin may have induced tolerance as was recently hypothesised
[44]. Thus the route of infection and initial infection load may, in
part, explain the differences. Moreover, human subjects have to be
drug cured when positive on a thick smear, while a longer
observation window (up to 2% parasitaemia) was possible for the
animals, thus the control of parasitaemia as observed in the
current study could not have been observed in a phase IIa setting.
In any case, it will be interesting to compare mosquito challenge
with blood-stage challenge in PkAMA1-vaccinated rhesus mon-
keys in future studies.
A recently reported phase IIb trial with AMA1 formulated in
AS02 in Malian children [23] revealed a hint of protection (17%,
not significant) against all P. falciparum infections, but significant
protection (64%) when infections with parasites bearing an AMA1
homologous to the vaccine antigen were considered. Infections
occurred against a background of pre-existing immunity which
was boosted by PfAMA1 vaccination; a situation similar to that of
the animals at the second and third challenges.
The protection observed in Malian children [23], the Aotus model
[8] and in the current study, suggest that phase IIa studies for down-
selection of vaccine candidates may need to be interpreted carefully.
It would be interesting to explore whether clinically relevant
protection would have been observed if the subjects in the AMA1
Phase IIa study [20] were boosted and re-challenged, as a series of
vaccinations followed by infection and booster immunisation could
be considered representative for the field situation.
In addition, the PkAMA1 vaccine candidate described here may
also be an attractive human vaccine candidate given the fact that
Plasmodium knowlesi is a zoonosis that affects humans and may be a
contributing cause of death [13,14].
Supporting Information
Figure S1 Relation between total IgG and GIA titre in
PkAMA1-vaccinated animals. Panel A: Day 70, Panel B: Day
217 and Panel C: Day 450. The amount of total IgG is depicted on
the x-axis and the corresponding growth inhibition is depicted on
the y-axis. The IC50 values are indicated by the red lines.
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